BACKGROUND

Stemnovate’s compliant organs-on-chip platforms integrate stem cell research and tissue engineering to provide physiological alternative to cancer lines and animal models for precision drug discovery and screening. It takes, on average, 10-15 years to launch a new drug, costing approximately 5 billion USD. And, with costs increasing year on year, many in the pharmaceutical industry feel this trend is untenable. With this level of investment in terms of time, resources, and funds, the occurrence of drug failures and market withdrawals can have a substantial financial impact, as well as posing a significant level of risk to the health of patients. Our platform technology provides an opportunity to execute the vision of high-throughput and cost-effective drug discovery.


STEMNOVATE TIMELINE
2016
Founded April 2016
2017
Project lead
  • Innovate UK grant funding –1 million USD
2017
Angel Investment

European Union

2018
Operations & Licenses
  • IPS Acedemia Japan
  • University of Edinburgh
  • HTA
2019
Partnership & Collaboration
  • International
  • National
2019
Liver on chip platform market launch
2020
Data platform launch


MISSION
Our mission is to take science and technology advancements beyond publications. We are disrupting and changing the present inefficient processes with the products and services that accelerate drug discovery so that the health benefits reach the global community faster and cost-effectively.
Mission
VISION
The big vision is to make personalised medicine a global reality through smart devices and data platforms, ensuring efficient drug discovery, diagnostics and targeted treatments.
Vision